Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
S-phase cancer associated transcript 2 (SCAT2) is a long non-coding RNA (lncRNA), also named CBX5-AS1, located on chromosome 12[1][5][9]. It is transcribed in the antisense orientation relative to the CBX5 gene, which encodes heterochromatin protein 1 alpha (HP1α). While the specific biological functions of SCAT2 are still being elucidated, lncRNAs like SCAT2 can regulate gene expression by interacting with DNA, RNA, or proteins, affecting pathways such as cell cycle progression and cancer phenotype[3]. SCAT2 has been reported in cancer transcriptome analyses and is classified by authoritative sources as a cancer-associated lncRNA, but it is not currently known to be a direct target for any approved therapeutic drugs[5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on S-phase cancer associated transcript 2 (SCAT2).